For more than two years it had the entirety of the market for weight-loss drugs to itself. By 2023 sales of Wegovy had ...

Even so, in an interview with The Economist, Mr Doustdar sounded confident that Novo can recover. His prescription is to push ...

NEW YORK, Dec 10 (Reuters) - Online telehealth company Hims and Hers Health is launching its weight-loss membership and ...

Hims & Hers Health has sold off ~40% GLP-1 turbulence, but the core growth story remains intact. Read why HIMS stock is a ...

Online telehealth company Hims and Hers Health HIMS.N is launching its weight-loss membership and treatment plans in the UK ...

Eli Lilly LLY announced that it has lowered the price of single-dose vials of its blockbuster obesity drug, Zepbound ...

One of largest U.S. telehealth providers expects to ride wave of exploding demand for weight-loss drug semaglutide when it ...

The renowned health and wellness platform, Hims & Hers Health, Inc.’s HIMS, business model links virtual consultations directly to prescription access and home delivery. Customers meet with ...

The obesity drug producer has taken some hits throughout the past year, but it is beginning to punch back.

A newly released survey from over 3,000 Americans indicates that people 45 years old and over are becoming increasingly lonely.

Novo Nordisk enters the final stretch of 2025 looking almost unrecognizable from the market darling it was just months ago.

Healthy people are injecting tiny doses of obesity medication to look and feel even better. But at what risk?